Search

Your search keyword '"Nations, Sharon P"' showing total 35 results
Start Over Author "Nations, Sharon P" Language english
35 results on '"Nations, Sharon P"'

1. Safety and efficacy of intravenous bimagrumab in inclusion body myositis (RESILIENT): a randomised, double-blind, placebo-controlled phase 2b trial

Author

Hanna, Michael G, Badrising, Umesh A, Benveniste, Olivier, Lloyd, Thomas E, Needham, Merrilee, Chinoy, Hector, Aoki, Masashi, Machado, Pedro M, Liang, Christina, Reardon, Katrina A, de Visser, Marianne, Ascherman, Dana P, Barohn, Richard J, Dimachkie, Mazen M, Miller, James A L, Kissel, John T, Oskarsson, Björn, Joyce, Nanette C, Van den Bergh, Peter, Baets, Jonathan, De Bleecker, Jan L, Karam, Chafic, David, William S, Mirabella, Massimiliano, Nations, Sharon P, Jung, Hans H, Pegoraro, Elena, Maggi, Lorenzo, Rodolico, Carmelo, Filosto, Massimiliano, Shaibani, Aziz I, Sivakumar, Kumaraswamy, Goyal, Namita A, Mori-Yoshimura, Madoka, Yamashita, Satoshi, Suzuki, Naoki, Katsuno, Masahisa, Murata, Kenya, Nodera, Hiroyuki, Nishino, Ichizo, Romano, Carla D, Williams, Valerie S L, Vissing, John, Auberson, Lixin Zhang, Wu, Min, de Vera, Ana, Papanicolaou, Dimitris A, and Amato, Anthony A

Published
2019
Full Text
View/download PDF

2. Editorial by concerned physicians: Unintended effect of the orphan drug act on the potential cost of 3,4-diaminopyridine

Author

Burns, Ted M., Smith, Gordon A., Allen, Jeffrey A., Amato, Anthony A., Arnold, David W., Barohn, Richard, Benatar, Michael, Bird, Shawn J., Bromberg, Mark, Chahin, Nizar, Ciafaloni, Emma, Cohen, Jeffrey A., Corse, Andrea, Crum, Brian A., David, William S., Dimberg, Elliot, Sousa, Eduardo A. De, Donofrio, Peter D., Dyck, James P. B., Engel, Andrew G., Ensrud, Erik R., Ferrante, Mark, Freimer, Miriam, Gable, Karissa L., Gibson, Summer, Gilchrist, James M., Goldstein, Jonathan M., Gooch, Clifton L., Goodman, Brent P., Gorelov, Dmitri, Gospe, Sidney M., Jr., Goyal, Namita A., Guidon, Amanda C., Guptill, Jeffrey T., Gutmann, Laurie, Gutmann, Ludwig, Gwathmey, Kelly, Harati, Yadollah, Harper, Michel C., Jr., Hehir, Michael K., Hobson-Webb, Lisa D., Howard, James F., Jr., Jackson, Carlayne E., Johnson, Nicholas, Jones, Sarah M., Juel, Vern C., Kaminski, Henry J., Karam, Chafic, Kennelly, Kathleen D., Khella, Sami, Khoury, Julie, Kincaid, John C., Kissel, John T., Kolb, Noah, Lacomis, David, Ladha, Shafeeq, Larriviere, Daniel, Lewis, Richard A., Li, Yuebing, Litchy, William J., Logigian, Eric, Lou, Jau-Shin, MacGowen, Daniel J.L., Maselli, Ricardo, Massey, Janice M., Mauermann, Michelle L., Mathews, Katherine D., Meriggioli, Matthew N., Miller, Robert G., Moon, Joon-Shik, Mozaffar, Tahseen, Nations, Sharon P., Nowak, Richard J., Ostrow, Lyle W., Pascuzzi, Robert M., Peltier, Amanda, Ruzhansky, Katherine, Richman, David P., Ross, Mark A., Rubin, DEVON I., Russell, James A., Sachs, George M., Salajegheh, Mohammad Kian, Saperstein, David S., Scelsa, Stephen, Selcen, Duygu, Shaibani, Aziz, Shieh, Perry B., Silvestri, Nicholas J., Singleton, Rob J., Smith, Benn E., So, Yuen T., Solorzano, Guillermo, Sorenson, Eric J., Srinivasen, Jayashri, Tavee, Jinny, Tawil, Rabi, Thaisetthawatkul, Pariwat, Thornton, Charles, Trivedi, Jaya, Vernino, Steven, Wang, Annabel K., Webb, Tyler A., Weiss, Michael D., Windebank, Anthony J., and Wolfe, Gil I.

Published
2016
Full Text
View/download PDF

4. Efficacy and Safety of Bimagrumab in Sporadic Inclusion Body Myositis: Long-term Extension of RESILIENT

Author

Amato, Anthony A, Hanna, Michael G, Machado, Pedro M, Badrising, Umesh A, Chinoy, Hector, Benveniste, Olivier, Karanam, Ananda Krishna, Wu, Min, Tankó, László B, Schubert-Tennigkeit, Agnes Annette, Papanicolaou, Dimitris A, Lloyd, Thomas E, Needham, Merrilee, Liang, Christina, Reardon, Katrina A, de Visser, Marianne, Ascherman, Dana P, Barohn, Richard J, Dimachkie, Mazen M, Miller, James A L, Kissel, John T, Oskarsson, Björn, Joyce, Nanette C, Van den Bergh, Peter, Baets, Jonathan, De Bleecker, Jan L, Karam, Chafic, David, William S, Mirabella, Massimiliano, Nations, Sharon P, et al, and University of Zurich

Subjects
2728 Neurology (clinical), 610 Medicine & health, 10040 Clinic for Neurology
Published
2021

8. Phase 2 Trial of Rituximab in Acetylcholine Receptor Antibody-Positive Generalized Myasthenia Gravis: The BeatMG Study.

Author

Nowak, Richard J., Coffey, Christopher S., Goldstein, Jonathan M., Dimachkie, Mazen M., Benatar, Michael, Kissel, John T., Wolfe, Gil I., Burns, Ted M., Freimer, Miriam L., Nations, Sharon, Granit, Volkan, Smith, A. Gordon, Richman, David P., Ciafaloni, Emma, Al-Lozi, Muhammad T., Sams, Laura Ann, Quan, Dianna, Ubogu, Eroboghene, Pearson, Brenda, and Sharma, Aditi

Published
2022
Full Text
View/download PDF

18. Plasma creatinine and oxidative stress biomarkers in amyotrophic lateral sclerosis.

Author

Mitsumoto, Hiroshi, Garofalo, Diana C., Santella, Regina M., Sorenson, Eric J., Oskarsson, Björn, Fernandes, J americo M., Andrews, Howard, Hupf, Jonathan, Gilmore, Madison, Heitzman, Daragh, Bedlack, Richard S., Katz, Jonathan S., Barohn, Richard J., Kasarskis, Edward J., lomen-Hoerth, Catherine, Mozaffar, Tahseen, Nations, Sharon P., Swenson, Andrea J., and Factor-Litvak, Pam

Subjects
AMYOTROPHIC lateral sclerosis, OXIDATIVE stress, CREATININE, BIOMARKERS, URIC acid
Abstract

Objective: To determine the associations between plasma creatinine (PCr), plasma uric acid (PUA), and urinary oxidative stress (OS) biomarkers with the ALSFRS-R at baseline and survival in a large epidemiological cohort study (ALS COSMOS) with a well-phenotyped patient population (N = 355). Methods: Fasting plasma and first void urine samples were obtained. PCr, PUA, urinary 8-oxo-deoxy guanosine (8-oxodG), and 15-F2t-isoprostane (IsoP) were analyzed at baseline, near the midpoint of follow-up, and at the final blood draw (before death or withdrawal from study). We estimated associations between these biomarkers and the ALSFRS-R at baseline and survival. Results: At baseline, PCr correlated with ALSFRS-R (Spearman r = 0.30), percent (%) FVC (r = 0.20), PUA (r = 0.37), and 8-oxodG (r = −0.13, all p < 0.05). Baseline PCr significantly predicted survival (adjusted hazard ratio 0.28, p < 0.001). Time to death from baseline was shortest for those in the lowest two PCr quartiles relative to the highest two quartiles. PCr and ALSFRS-R values were significantly correlated at all three time points (baseline: r = 0.29, midpoint: r = 0.23, final: r = 0.38, all p < 0.001). PCr and PUA significantly declined over time, whereas OS biomarkers significantly increased over time. Conclusions: To date, PCr predicted survival the best, compared to PUA, 8-oxodG, and IsoP. Although PCr represents the degree of muscle mass, it may also represent complex biochemical changes in ALS. Because the field has no reliable prognostic biomarkers, the importance of PCr warrants further investigation through clinical studies in ALS. [ABSTRACT FROM AUTHOR]

Published
2020
Full Text
View/download PDF

19. Rasagiline for amyotrophic lateral sclerosis: A randomized, controlled trial.

Author

Statland, Jeffrey M., Moore, Dan, Wang, Yunxia, Walsh, Maureen, Mozaffar, Tahseen, Elman, Lauren, Nations, Sharon P., Mitsumoto, Hiroshi, Fernandes, J. Americo, Saperstein, David, Hayat, Ghazala, Herbelin, Laura, Karam, Chafic, Katz, Jonathan, Wilkins, Heather M., Agbas, Abdulbaki, Swerdlow, Russell H., Santella, Regina M., Dimachkie, Mazen M., and Barohn, Richard J.

Subjects
AMYOTROPHIC lateral sclerosis, COMPARATIVE studies, HYDROCARBONS, RESEARCH methodology, MEDICAL cooperation, HEALTH outcome assessment, QUALITY of life, RESEARCH, RESEARCH funding, DNA-binding proteins, EVALUATION research, RANDOMIZED controlled trials, TREATMENT effectiveness, NEUROPROTECTIVE agents, BLIND experiment, RETROSPECTIVE studies, SEVERITY of illness index
Abstract

Introduction: Rasagiline is a monoamine oxidase B (MAO-B) inhibitor with possible neuroprotective effects in patients with amyotrophic lateral sclerosis (ALS).Methods: We performed a randomized, double-blind, placebo-controlled trial of 80 ALS participants with enrichment of the placebo group with historical controls (n = 177) at 10 centers in the United States. Participants were randomized in a 3:1 ratio to 2 mg/day rasagiline or placebo. The primary outcome was average slope of decline on the ALS Functional Rating Scale-Revised (ALSFRS-R). Secondary measures included slow vital capacity, survival, mitochondrial and molecular biomarkers, and adverse-event reporting.Results: There was no difference in the average 12-month ALSFRS-R slope between rasagiline and the mixed placebo and historical control cohorts. Rasagiline did not show signs of drug-target engagement in urine and blood biomarkers. Rasagiline was well tolerated with no serious adverse events.Discussion: Rasagiline did not alter disease progression compared with controls over 12 months of treatment. Muscle Nerve 59:201-207, 2019. [ABSTRACT FROM AUTHOR]

Published
2019
Full Text
View/download PDF

21. Cognitive-behavioral screening reveals prevalent impairment in a large multicenter ALS cohort.

Author

Murphy, Jennifer, Factor-Litvak, Pam, Goetz, Raymond, Lomen-Hoerth, Catherine, Nagy, Peter L., Hupf, Jonathan, Singleton, Jessica, Woolley, Susan, Andrews, Howard, Heitzman, Daragh, Bedlack, Richard S., Katz, Jonathan S., Barohn, Richard J., Sorenson, Eric J., Oskarsson, Björn, Fernandes Filho, J. Americo M., Kasarskis, Edward J., Mozaffar, Tahseen, Rollins, Yvonne D., and Nations, Sharon P.

Published
2016
Full Text
View/download PDF

22. Challenges in the Identification of Cobalamin-Deficiency Polyneuropathy.

Author

David S. Saperstein, Wolfe, Gil I., Gronseth, Gary S., Nations, Sharon P., Herbelin, Laura L., Bryan, Wilson W., and Barohn, Richard J.

Subjects
POLYNEUROPATHIES, VITAMIN B12 deficiency, METABOLITES
Abstract

Background: Diagnosing cobalamin (Cbl) deficiency as a cause of polyneuropathy (PN) is problematic, as the frequency of both disorders increases with age, and serum Cbl levels can be difficult to interpret. Objectives: To identify unique clinical or laboratory features among PN patients with Cbl deficiency and to examine the role of testing of serum metabolite levels in the identification of Cbl deficiency. Design: Cohort survey comparing patients with Cbl deficiency and cryptogenic PN identified during a 2-year period. Cobalamin deficiency was diagnosed using low serum Cbl levels or elevated serum methylmalonic acid or homocysteine levels. Setting: Academic neuromusclar clinic. Results: Of 324 PN patients, 27 were diagnosed as having Cbl deficiency. Twelve had Cbl levels within the normal range, but elevated serum metabolite levels. Compared with patients with cryptogenic sensory/sensorimotor PN, those with Cbl deficiency were more likely to have concomitant involvement of the upper and lower extremities and experience symptom onset in the hands and a sudden onset of symptoms (P<.005). These differences were seen regardless of whether Cbl deficiency was defined using low Cbl levels or elevated serum metabolite levels. Autoimmune pernicious anemia was identified in 6 (50%) of 12 Cbl-deficient patients with normal serum Cbl levels. The patients with PN and Cbl deficiency showed little objective improvement after parenteral replacement therapy; however, progression occurred less often in these patients compared with those with cryptogenic sensory/sensorimotor PN (P = .02). Conclusions: This study highlights the challenges of proving that Cbl deficiency is the cause for PN and identifies clinical features that suggest Cbl-deficiency PN. Testing of serum metabolite levels may identify Cbl deficiency in some patients with normal serum Cbl levels. [ABSTRACT FROM AUTHOR]

Published
2003
Full Text
View/download PDF

32. Contributors

Author

Adams, Robert J., Albers, James W., Alderson, Lloyd M., Alexander, Michael P., Amato, Anthony A., Amin-Hanjani, Sepideh, Armstrong, Richard M., Aronoff, Gerald M., Arora, Ajay K., Ashizawa, Tetsuo, Babikian, Viken L., Baehring, Joachim M., Bajwa, Zahid H., Baloh, Robert W., Barnes, Patrick D., Barohn, Richard J., Baskin, Steven M., Bella, Isabelita R., Benjamin, Richard J., Berger, Alan R., Bergman, Susan Biener, Bigal, Marcelo E., Biller, José, Black, Peter McLaren, Bolton, Charles F., Borsook, David, Brass, Lawrence M., Brillman, Jon, Bromfield, Edward B., Brown, Robert H., Jr., Brust, John C.M., Caplan, Louis R., Chad, David A., Charness, Michael E., Chimowitz, Marc I., Cho, Catherine, Chuang, Cathy, Churchill, Winthrop H., Cohen, Alan R., Cole, Douglas G., Conomy, John P., Dacso, Clifford C., Daffner, Kirk R., Dalmau, Josep O., Darras, Basil T., Davis, Patricia H., Dawson, David M., DeAngelis, Lisa M., Girolami, Umberto De, DeWitt, L. Dana, D'Olhaberriague, Luis, Drislane, Frank W., Dropcho, Edward J., Ehrenberg, Bruce, Eichler, Marc E., Estol, Conrado J., Evans, Bradley K., Fanciullo, Gilbert J., Feldman, Robert G., Feske, Steven K., Fishman, Scott M., Fogel, Barry S., Freeman, Roy L., Friedman, Joseph H., Frosch, Matthew P., Frumin, Melissa, Furlan, Anthony J., Gates, George A., Geckle, David S., Giordano, Thomas P., Glenn, Mel B., Goldstein, Martin A., Gomez, Christopher M., Gooch, Clifton L., Graus, Francesc R., Greenberg, Harry S., Greenberg, Stephen B., Greer, Melvin, Griggs, Robert C., Gross, Sheldon G., Grossman, Stuart A., Gruber, Michael L., Gutmann, Ludwig, Hall, Walter A., Hallett, Mark, Hammack, Julie E., Harati, Yadollah, Harris, Richard L., Hawkes, Christopher H., Hayes, Michael T., Herrmann, David N., Hochberg, Fred H., Hollander, Dave, Holmes, Gregory L., Hsu, Liangge, Jacobson, Daniel M., Jamison, Robert N., Jankovic, Joseph, Jeerakathil, Tom J., Johns, Donald R., Jones, H. Royden, Jr., Kaminski, Henry J., Karanjia, Percy N., Kase, Carlos S., Katirji, Bashar, Katz, Jonathan S., Katz, Nathaniel P., Kelly, John J., Jr., Kern, Drew S., Khoshbin, Shahram, Kirshner, Howard S., Kolodny, Edwin H., Korf, Bruce R., Koroshetz, Walter J., Krupp, Lauren B., Kudrow, David B., Kumar, Rajeev, Kunkel, Robert S., Kurlan, Roger, Lacomis, David, Lai, Eugene C., Laureno, Robert, LaViolette, Susan, Lee, J. Douglas, Levine, Edward J., Levine, Robert Aaron, Levine, Steven R., LeWitt, Peter, Libenson, Mark H., Lipton, Richard B., Liu, Grant T., Loder, Elizabeth W., Loeffler, Jay S., Logigian, Eric L., Love, Betsy B., Lovitt, Steven, Macklis, Jeffrey D., Mankodi, Ami K., Marshall, Frederick J., Marshall, Randall S., Matheson, Jean K., McEvoy, Kathleen, McKendall, Robert R., Miller, Daniel, Miyawaki, Edison, Mohr, J.P., Molloy, Fiona, Moore, Patricia M., Mufson, Michael, Nations, Sharon P., Nolan, Craig Patrick, Nolan, Patrick E., Norregaard, Thorkild V., North, Kathryn N., O'Donovan, Cormac A., Ohaegbulam, Chima O., Olney, Richard K., Packard, Russell C., Park, John K., Patchell, Roy A., Peteet, John R., Petersen, Ronald C., Peterson, Kendra, Pickett, Jackson B., Pirl, William F., Plotkin, Scott R., Pomeroy, Scott L., Potts, Frisso, Press, Daniel, Preston, David C., Price, Bruce H., Pruitt, Amy, Pulley, Michael T., Ramakrishna, Naren, Rapoport, Alan M., Ravin, Paula, Raynor, Elizabeth M., Recht, Lawrence D., Reed, Kurt, Rentz, Dorene M., Richardson, Gary S., Robbins, Jeffrey M., Rodriguez, Diana L., Rolak, Loren, Ronthal, Michael, Roth, Patrick A., Rothstein, Jeffrey D., Ruff, Robert L., Russell, James A., Sabin, Thomas D., Sadek, Ahmed H., Salmanson, Eileen, Samuel, Nalini, Samuels, Martin A., Schachter, Steven C., Schiff, David, Schomer, Donald, Schumacher, H. Christian, Scott, R. Michael, Sekul, Elizabeth A., Shapiro, Barbara E., Sharma, Nutan, Shefner, Jeremy M., Sheftell, Fred D., Shrieve, Dennis C., Siffert, Joao O., Sila, Cathy A., Singer, Carlos, Sipski, Marca L., Specht, Linda A., Spierings, Egilius L.H., Spindel, Steven, Stern, Barney J., Stone, Lael A., Suarez, Guillermo A., Sudarsky, Lewis R., Swoboda, Kathryn, Talman, William T., Tarbell, Nancy J., Tarsy, Daniel, Teal, Philip A., Teoh, Siew Koon, Thompson, Daryl W., Tyor, William R., Venna, Nagagopal, Vernick, David M., Walker, Aljoeson, Warfield, Carol A., Waters, Cheryl, Wechsler, Lawrence R., Weeks, Randall E., Weinberg, David H., Weintraub, Sandra, Wen, Dennis Y., Wen, Patrick Y.C., Wiesman, Janice F., Wilbourn, Asa J., Williams, Temple W., Jr., Wilsey, Barth L., Wolf, Philip A., Young, G. Bryan, and Zamani, Amir

Full Text
View/download PDF

33. Efficacy and Safety of Bimagrumab in Sporadic Inclusion Body Myositis: Long-term Extension of RESILIENT.

Author

Amato AA, Hanna MG, Machado PM, Badrising UA, Chinoy H, Benveniste O, Karanam AK, Wu M, Tankó LB, Schubert-Tennigkeit AA, Papanicolaou DA, Lloyd TE, Needham M, Liang C, Reardon KA, de Visser M, Ascherman DP, Barohn RJ, Dimachkie MM, Miller JAL, Kissel JT, Oskarsson B, Joyce NC, Van den Bergh P, Baets J, De Bleecker JL, Karam C, David WS, Mirabella M, Nations SP, Jung HH, Pegoraro E, Maggi L, Rodolico C, Filosto M, Shaibani AI, Sivakumar K, Goyal NA, Mori-Yoshimura M, Yamashita S, Suzuki N, Aoki M, Katsuno M, Morihata H, Murata K, Nodera H, Nishino I, Romano CD, Williams VSL, Vissing J, and Zhang Auberson L

Subjects
Accidental Falls, Adult, Aged, Aged, 80 and over, Double-Blind Method, Female, Humans, Male, Middle Aged, Muscle Strength drug effects, Myositis, Inclusion Body complications, Time, Treatment Outcome, Walk Test, Antibodies, Monoclonal, Humanized therapeutic use, Myositis, Inclusion Body drug therapy
Abstract

Objective: To assess long-term (2 years) effects of bimagrumab in participants with sporadic inclusion body myositis (sIBM)., Methods: Participants (aged 36-85 years) who completed the core study (RESILIENT [Efficacy and Safety of Bimagrumab/BYM338 at 52 Weeks on Physical Function, Muscle Strength, Mobility in sIBM Patients]) were invited to join an extension study. Individuals continued on the same treatment as in the core study (10 mg/kg, 3 mg/kg, 1 mg/kg bimagrumab or matching placebo administered as IV infusions every 4 weeks). The co-primary outcome measures were 6-minute walk distance (6MWD) and safety., Results: Between November 2015 and February 2017, 211 participants entered double-blind placebo-controlled period of the extension study. Mean change in 6MWD from baseline was highly variable across treatment groups, but indicated progressive deterioration from weeks 24-104 in all treatment groups. Overall, 91.0% (n = 142) of participants in the pooled bimagrumab group and 89.1% (n = 49) in the placebo group had ≥1 treatment-emergent adverse event (AE). Falls were slightly higher in the bimagrumab 3 mg/kg group vs 10 mg/kg, 1 mg/kg, and placebo groups (69.2% [n = 36 of 52] vs 56.6% [n = 30 of 53], 58.8% [n = 30 of 51], and 61.8% [n = 34 of 55], respectively). The most frequently reported AEs in the pooled bimagrumab group were diarrhea 14.7% (n = 23), involuntary muscle contractions 9.6% (n = 15), and rash 5.1% (n = 8). Incidence of serious AEs was comparable between the pooled bimagrumab and the placebo group (18.6% [n = 29] vs 14.5% [n = 8], respectively)., Conclusion: Extended treatment with bimagrumab up to 2 years produced a good safety profile and was well-tolerated, but did not provide clinical benefits in terms of improvement in mobility. The extension study was terminated early due to core study not meeting its primary endpoint., Clinical Trial Registration: Clinicaltrials.gov identifier NCT02573467., Classification of Evidence: This study provides Class IV evidence that for patients with sIBM, long-term treatment with bimagrumab was safe, well-tolerated, and did not provide meaningful functional benefit. The study is rated Class IV because of the open-label design of extension treatment period 2., (© 2021 American Academy of Neurology.)

Published
2021
Full Text
View/download PDF

34. ALS Multicenter Cohort Study of Oxidative Stress (ALS COSMOS): study methodology, recruitment, and baseline demographic and disease characteristics.

Author

Mitsumoto H, Factor-Litvak P, Andrews H, Goetz RR, Andrews L, Rabkin JG, McElhiney M, Nieves J, Santella RM, Murphy J, Hupf J, Singleton J, Merle D, Kilty M, Heitzman D, Bedlack RS, Miller RG, Katz JS, Forshew D, Barohn RJ, Sorenson EJ, Oskarsson B, Fernandes Filho JA, Kasarskis EJ, Lomen-Hoerth C, Mozaffar T, Rollins YD, Nations SP, Swenson AJ, Shefner JM, Andrews JA, and Koczon-Jaremko BA

Subjects
Aged, Amyotrophic Lateral Sclerosis genetics, Amyotrophic Lateral Sclerosis metabolism, Cohort Studies, Demography, Disease Progression, Female, Humans, Insurance Coverage statistics & numerical data, Male, Middle Aged, Skin pathology, Surveys and Questionnaires, Time Factors, United States, Amyotrophic Lateral Sclerosis epidemiology, Amyotrophic Lateral Sclerosis physiopathology, Oxidative Stress physiology, Patient Selection
Abstract

Abstract In a multicenter study of newly diagnosed ALS patients without a reported family history of ALS, we are prospectively investigating whether markers of oxidative stress (OS) are associated with disease progression. Methods utilize an extensive structured telephone interview ascertaining environmental, lifestyle, dietary and psychological risk factors associated with OS. Detailed assessments were performed at baseline and at 3-6 month intervals during the ensuing 30 months. Our biorepository includes DNA, plasma, urine, and skin. Three hundred and fifty-five patients were recruited. Subjects were enrolled over a 36-month period at 16 sites. To meet the target number of subjects, the recruitment period was prolonged and additional sites were included. Results showed that demographic and disease characteristics were similar between 477 eligible/non-enrolled and enrolled patients, the only difference being type of health insurance among enrolled patients. Sites were divided into three groups by the number of enrolled subjects. Comparing these three groups, the Columbia site had fewer 'definite ALS' diagnoses. This is the first prospective, interdisciplinary, in-depth, multicenter epidemiological investigation of OS related to ALS progression and has been accomplished by an aggressive recruitment process. The baseline demographic and disease features of the study sample are now fully characterized.

Published
2014
Full Text
View/download PDF

35. Benefit of IVIg for long-standing ataxic sensory neuronopathy with Sjögren's syndrome.

Author

Wolfe GI, Nations SP, Burns DK, Herbelin LL, and Barohn RJ

Subjects
Adult, Autoimmune Diseases of the Nervous System genetics, Female, Gait Ataxia therapy, Humans, Polyneuropathies therapy, Remission Induction, Sensation Disorders therapy, Sjogren's Syndrome complications, Sjogren's Syndrome genetics, Autoimmune Diseases of the Nervous System therapy, Gait Ataxia etiology, Immunoglobulins, Intravenous therapeutic use, Immunosuppressive Agents therapeutic use, Polyneuropathies etiology, Sensation Disorders etiology, Sjogren's Syndrome therapy
Published
2003

Catalog

Books, media, physical & digital resources
See catalog results